In addition to reflecting the spontaneous immune-activated status of the tumor, gene signatures related to IFNG response are widely associated with the expression of immune checkpoints, tumor mutational burden (TMB), responsiveness to immunotherapy, and clinical outcomes of various cancers (19, 20). The gene discussed is IFNG; the disease is neoplasm.